Search
Annually, Gerstner Sloan Kettering recognizes student research through fellowship awards with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.
New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the origins of ERG-driven prostate cancer; and finds Dupilumab is a successful agent to treat skin toxicities related to antibody-drug conjugates.
MSK’s Kathryn Beal presents new findings on combining radiation with immunotherapy for brain cancer.
Resection of all residual disease after salvage chemotherapy offers the best chance for a cure for patients with refractory or relapsed advanced testicular cancer, according to the results of our recent retrospective study.
Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan Kettering from Massachusetts General Hospital.
A study reveals unexpected insights into how cells prepare broken DNA strands to be rejoined, preventing mutations that can cause cancer.
Learn how eating a plant-based diet may prevent MGUS and smoldering myeloma from developing into multiple myeloma, according to MSK research.
In the largest-ever genetic analysis of people being treated with checkpoint inhibitors, Memorial Sloan Kettering researchers looked at patients who received several checkpoint inhibitors for a number of different cancers at many different hospitals. Researchers found that people who had a greater diversity and more variation in their human leukocyte antigen (HLA) genes responded much better to immunotherapy compared with those who had less diversity. For more information or to speak with an expert, contact Rebecca Williams at [email protected].
Can turmeric fight cancer? Learn more from an MSK expert about what the science says.
The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), made possible by a generous $40 million gift from Henry R. Kravis to honor the visionary leadership of his wife, Marie-Josée Kravis, will establish a strategic research infrastructure that will seamlessly unite MSK scientists and physicians to further accelerate immunotherapy treatments for people with cancer.